Skip to main content
main-content

Prostate cancer

Expert commentary

04-06-2020 | ASCO 2020 | Conference coverage | Video

Expert highlights: Genitourinary cancers at ASCO 2020

Axel Merseburger takes us through his picks of the genitourinary cancers track of the virtual 2020 ASCO Annual Meeting, including the JAVELIN Bladder 100 and KEYNOTE-426 trials (10:28).

01-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Initial data from CCC19

Jeremy Warner provides a comprehensive overview of the findings from the first 1018 patients with cancer and COVID-19 enrolled in the CCC19 registry (14:40).

31-05-2020 | ASCO 2020 | Conference coverage | Video

Expert comment: Antiandrogens in nonmetastatic CRPC

Tomasz Beer highlights the key messages and caveats of the overall survival data from the PROSPER, SPARTAN, and ARAMIS trials of enzalutamide, apalutamide, and darolutamide, respectively, in the nonmetastatic castration-resistant prostate cancer setting (10:25).

31-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The TheraP trial

Michael Hofman explains why the TheraP study of LuPSMA versus cabazitaxel in men with metastatic castration-resistant prostate cancer is even more relevant in light of the recently reported CARD trial (4:24).

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The SPARTAN OS data

Boris Hadaschik discusses the final overall survival analysis of the phase 3 placebo-controlled SPARTAN trial of apalutamide for nonmetastatic castration-resistant prostate cancer (6:00).

25-03-2020 | Genitourinary cancers | Podcast | Audio

Managing patients with genitourinary cancers in the time of COVID-19

Genitourinary oncologists Cora Sternberg and Axel Merseburger share their experience of managing cancer patients during the COVID-19 pandemic, comparing perspectives from a US and German stand point.

07-10-2019 | Prostate cancer | Video | Article

Expert comment: The STAMPEDE study

Eleni Efstathiou shares her views on the STAMPEDE analysis indicating that docetaxel may be an option for hormone-naïve prostate cancer regardless of metastatic disease burden (2:16).

04-10-2019 | Castration-resistant prostate cancer | Video | Article

Researcher comment: Cabazitaxel a new third-line option in mCRPC

Ronald de Wit tells us why the CARD trial results are likely to change the paradigm for the treatment of metastatic castration-resistant prostate cancer (3:58).

03-10-2019 | Castration-resistant prostate cancer | Video | Article

Researcher comment: PROfound improvement in outcomes with olaparib in mCRPC

The PROfound trial evaluated olaparib in metastatic castration-resistant prostate cancer ─ Maha Hussain discusses the clinical implications and practical applications of the findings (2:40).

02-10-2019 | Castration-resistant prostate cancer | Video | Article

Expert comment: The CARD trial

Silke Gillessen comments on the phase IV CARD study investigating third-line cabazitaxel in men with metastatic castration-resistant prostate cancer (3:02). 

02-10-2019 | Castration-resistant prostate cancer | Video | Article

Expert comment: The PROfound trial

Eleni Efstathiou explains why the PROfound trial of the PARP inhibitor olaparib is the first step towards treating metastatic castration-resistant prostate cancer in a more precise way (3:09).

02-10-2019 | Genitourinary cancers | Video | Article

Expert highlights: Genitourinary cancers at ESMO 2019

Axel Merseburger takes us through his top picks of the genitourinary cancer research reported at the ESMO Congress 2019, including updates on the TITAN and STAMPEDE prostate cancer trials, the SORCE trial in renal cell carcinoma, and the investigation of first-line enfortumab vedotin in bladder cancer (5:33).

17-06-2019 | Prostate cancer | Video | Article

MRI-targeted biopsy for prostate cancer diagnosis

Veeru Kasivisvanathan explains the background and clinical implications of the PRECISION trial, which tested whether using multiparametric MRI with a targeted biopsy was noninferior to standard transrectal ultrasonography–guided biopsy in the detection of clinically significant prostate cancer.

04-06-2019 | Castration-sensitive prostate cancer | Video | Article

Expert comment: ENZAMET and TITAN trials

Earle Burgess provides an independent commentary on the ENZAMET and TITAN results presented at the 2019 ASCO Annual Meeting, and discusses what these data mean for patients and physicians (2:57).

04-06-2019 | Castration-sensitive prostate cancer | Video | Article

Researcher comment: OS boost with enzalutamide in metastatic CSPC setting

Christopher Sweeney presents the main findings of the ENZAMET trial, which evaluated the impact of supplementing androgen deprivation therapy with enzalutamide in men with advanced castration-sensitive prostate cancer (3:10).

01-06-2019 | Castration-sensitive prostate cancer | Video | Article

Researcher comment: Apalutamide addition improves metastatic CSPC survival

Study author Axel Merseburger takes us through the TITAN trial investigating the addition of apalutamide to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting, and also addresses the key question of how physicians should choose between the available treatment options (3:03).

15-11-2018 | Prostate cancer | Podcast | Audio

Researcher comment: COMPARE study

Hashim Ahmed takes us through the COMPARE study – presented at NCRI 2018 – which showed that men with localized prostate cancer are willing to make accept lower survival odds for a better quality of life. He outlines the key findings, the implications of the results for physicians, and the next steps for research (5:36).

Click here for the accompanying news story.

30-10-2018 | Castration-resistant prostate cancer | ESMO 2018 | Video

Abiraterone alone likely suppresses testosterone sufficiently in mCRPC patients

Carsten Ohlmann discusses findings of the phase II SPARE trial that investigated forgoing LHRH therapy in metastatic prostate cancer patients receiving abiraterone acetate (5:16).

06-07-2018 | Prostate cancer | Editorial | Article

Bipolar androgen therapy: Progress and future directions

Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both androgen deprivation and administration, which may potentially have benefit for prostate cancer patients.

02-07-2018 | Prostate cancer | Editorial | Article

Urinary biomarkers in the management of prostate cancer

Non-invasive biomarkers have the potential to guide and improve prostate cancer management in many ways. Maria Frantzi, Agnieszka Latosinska, and Harald Mischak (Mosaiques Diagnostics GmbH, Germany) outline some promising markers and what is needed to implement them in the clinic.

Image Credits